Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000517209 | SCV000614109 | pathogenic | not provided | 2017-04-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001060346 | SCV001225027 | pathogenic | Charcot-Marie-Tooth disease, type I | 2019-12-03 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine with lysine at codon 131 of the MPZ protein (p.Asn131Lys). The asparagine residue is highly conserved and there is a moderate physicochemical difference between asparagine and lysine. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individual(s) with Charcot-Marie-Tooth disease (PMID: 10553995, 12940837). It has also been observed to segregate with disease in related individuals. This variant is also known as 727C>A in the literature. ClinVar contains an entry for this variant (Variation ID: 14186). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000015250 | SCV000035509 | pathogenic | Roussy-Lévy syndrome | 1999-11-01 | no assertion criteria provided | literature only | |
Gene |
RCV000192587 | SCV000243904 | not provided | Charcot-Marie-Tooth disease type 1B | no assertion provided | literature only |